Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Sign Up
Cited by 574

The DOI matches its Crossref record; 86 of the 86 references it cites were found in a registry or an index.

An updated overview on the development of new photosensitizers for anticancer photodynamic therapy

Open access
Zhang, Juan, Jiang, Chengshi, Figueiró Longo, João Paulo, Azevedo, Ricardo Bentes, Zhang, Hua, Muehlmann, Luis Alexandre·2018·Acta Pharmaceutica Sinica B
DOI 10.1016/j.apsb.2017.09.003
Open this paper in CoChat — free account

Abstract

, belonging to the first generation of PS, is still widely used for the treatment of different kinds of cancers; however, it has several drawbacks that significantly limit its general clinical use. Consequently, there has been extensive research on the design of PS molecules with optimized pharmaceutical properties, with aiming of overcoming the disadvantages of traditional PS, such as poor chemical purity, long half-life, excessive accumulation into the skin, and low attenuation coefficients. The rational design of novel PS with desirable properties has attracted considerable research in the pharmaceutical field. This review presents an overview on the classical photosensitizers and the most significant recent advances in the development of PS with regard to their potential application in oncology.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.apsb.2017.09.003

Cites

86 of 86 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Cited by

See all 574

Metadata

Authors
Zhang, J., Jiang, C., Figueiró Longo, J. P., Azevedo, R. B., Zhang, H., & Muehlmann, L. A.
Venue
Acta Pharmaceutica Sinica B
Publisher
Elsevier BV
Published
2018-03
Volume
8
Issue
2
Pages
137-146
ISSN
2211-3835 (ISSN-L)
DOI
10.1016/j.apsb.2017.09.003
OpenAlex
W2758783177
Cited by
574
References
86
FWCI
37.46
Type
journal article
Language
en
Open access
gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.